Overview

Bicalutamide in Treating Patients With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2021-06-24
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such as bicalutamide, may stop the adrenal glands from making androgens. PURPOSE: This phase II trial is studying how well bicalutamide works in treating patients with metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
AstraZeneca
National Cancer Institute (NCI)
Treatments:
Bicalutamide